CYBQF: AI 评分 58/100 — AI 分析 (4月 2026)

CYBERDYNE Inc. is a Japanese company specializing in the development and production of robotic equipment, including the Hybrid Assistive Limb (HAL), for medical, welfare, and industrial applications. The company operates globally, offering solutions for rehabilitation, disaster relief, and heavy labor support.

Key Facts: AI Score: 58/100 Sector: Healthcare

公司概况

概要：

CYBERDYNE Inc. is a robotics company focused on developing and commercializing its Hybrid Assistive Limb (HAL) technology across medical, welfare, and industrial sectors. With a global presence and a focus on innovative cybernics solutions, CYBERDYNE aims to enhance human capabilities and address societal challenges, though profitability remains a key concern.

CYBQF是做什么的？

CYBERDYNE Inc., founded in 2004 and headquartered in Tsukuba, Japan, is a pioneering robotics company focused on the intersection of humans, machines, and information. The company's core technology is the Hybrid Assistive Limb (HAL), a wearable robot designed to enhance, support, and regenerate physical functions. HAL is used in various applications, including medical rehabilitation, welfare support, and industrial labor assistance. CYBERDYNE's product portfolio includes HAL for medical use (lower limb and single joint types), non-medical HAL (lower limb, single joint, and lumbar types), and HAL peripherals. Additionally, the company offers cleaning robots, transportation robots for indoor environments, Acoustic X (a high-speed light pulse LED array light source for photoacoustic imaging), and CYIN for living support (an interface using biological information). CYBERDYNE also provides Cybernics Treatment, which uses HAL to improve function in individuals with spinal cord injury, stroke, and neuromuscular diseases. The company's Neuro HALFIT program focuses on enhancing the brain-nerve-musculoskeletal system. CYBERDYNE operates globally, with a presence in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific region. The company's mission is to contribute to society by creating innovative cybernics solutions that address challenges in healthcare, welfare, and labor.

CYBQF的投资论点是什么？

CYBERDYNE Inc. presents a compelling, albeit high-risk, investment opportunity within the robotics and medical device sectors. The company's HAL technology has potential applications across various fields, including medical rehabilitation, industrial support, and entertainment. Key value drivers include the expansion of HAL's applications in new markets and the increasing adoption of Cybernics Treatment in healthcare. However, the company's negative profit margin of -0.1% and high P/E ratio of -22098.38 raise concerns about its financial sustainability. Growth catalysts include regulatory approvals for HAL in key markets and strategic partnerships to expand its distribution network. Investors should carefully consider the company's financial performance, competitive landscape, and regulatory hurdles before investing. The company's beta of 0.55 suggests lower volatility compared to the market.

CYBQF在哪个行业运营？

CYBERDYNE Inc. operates in the growing medical devices industry, which is driven by technological advancements, an aging population, and increasing demand for innovative healthcare solutions. The market for robotic rehabilitation devices is expected to expand significantly in the coming years. CYBERDYNE faces competition from established medical device companies and emerging robotics firms. Competitors include BCCOY (BICO AB), BRSYF (Brainsway Ltd), CHHHF (Choice Health at Home Inc.), CLLKF (Clearpoint Neuro Inc.), and JWCTF (Jupiter Wellness Acquisition Corp). CYBERDYNE's HAL technology differentiates it from competitors, but the company needs to demonstrate its ability to achieve profitability and gain market share.

Medical Devices

Healthcare

CYBQF有哪些增长机遇？

Expansion of HAL in Medical Rehabilitation: The market for robotic rehabilitation devices is growing due to the increasing prevalence of stroke, spinal cord injuries, and other neurological disorders. CYBERDYNE can capitalize on this trend by expanding the use of HAL in rehabilitation centers and hospitals globally. The global rehabilitation robotics market is projected to reach $1.7 billion by 2028. Success hinges on securing regulatory approvals and demonstrating HAL's clinical efficacy.
Adoption of Cybernics Treatment: Cybernics Treatment, which uses HAL to enhance and regenerate physical functions, represents a significant growth opportunity for CYBERDYNE. By expanding the availability of Cybernics Treatment in healthcare facilities, the company can generate recurring revenue and establish itself as a leader in regenerative medicine. The market for regenerative medicine is expected to reach $55 billion by 2025. Overcoming regulatory hurdles and demonstrating long-term clinical benefits are critical.
Industrial Applications of HAL: HAL can be used to support heavy labor in factories, plants, and construction sites, reducing the risk of injuries and improving productivity. CYBERDYNE can target industries with high physical demands and offer HAL as a solution to enhance worker safety and efficiency. The market for industrial exoskeletons is projected to reach $1.8 billion by 2027. Key to success is demonstrating HAL's cost-effectiveness and ease of use in industrial settings.
Disaster Relief and Rescue Support: CYBERDYNE can leverage HAL's capabilities to provide rescue support in disaster sites, assisting in search and rescue operations and providing aid to victims. By partnering with disaster relief organizations and government agencies, the company can contribute to humanitarian efforts and generate revenue. The market for disaster relief technologies is growing due to the increasing frequency and severity of natural disasters. Building strong relationships with key stakeholders is essential.
Entertainment Business: CYBERDYNE's engagement in the entertainment business, while currently a smaller part of its operations, presents an opportunity to diversify its revenue streams and enhance brand awareness. By developing interactive entertainment experiences using HAL technology, the company can attract a new customer base and generate excitement around its products. The market for location-based entertainment is projected to grow in the coming years. Success depends on creating compelling and engaging entertainment offerings.

Market capitalization of $0.27 billion indicates its size relative to competitors in the medical device industry.
Negative P/E ratio of -22098.38 reflects current unprofitability, requiring careful monitoring of future earnings potential.
Gross margin of 49.9% demonstrates the potential for profitability if operating expenses are managed effectively.
Beta of 0.55 suggests lower volatility compared to the market, potentially offering stability during market downturns.
No dividend yield indicates that the company is reinvesting earnings for growth, which may appeal to growth-oriented investors.

CYBQF提供哪些产品和服务？

Researches and develops robotic equipment and systems.
Produces and sells Hybrid Assistive Limb (HAL) devices for medical and welfare applications.
Leases HAL devices to healthcare facilities and other organizations.
Maintains HAL devices to ensure optimal performance and longevity.
Offers Cybernics Treatment using HAL for spinal cord injury, stroke, and neuromuscular diseases.
Provides Neuro HALFIT programs for enhancing brain-nerve-musculoskeletal system function.
Develops and sells cleaning and transportation robots for indoor environments.
Offers Acoustic X, a high-speed light pulse LED array light source for photoacoustic imaging.

CYBQF如何赚钱？

Sales and leasing of HAL devices to medical facilities, welfare organizations, and industrial clients.
Revenue from Cybernics Treatment and Neuro HALFIT programs.
Sales of cleaning robots, transportation robots, and other robotic equipment.
Maintenance and service contracts for HAL devices and other robotic systems.

Hospitals and rehabilitation centers using HAL for patient therapy.
Welfare organizations providing support to individuals with disabilities.
Factories and plants using HAL to assist workers with heavy labor.
Disaster relief organizations using HAL for rescue and support operations.

Proprietary HAL technology protected by patents and intellectual property.
First-mover advantage in the development of cybernics-based solutions.
Established relationships with key stakeholders in the medical, welfare, and industrial sectors.
Expertise in robotics, neuroscience, and biomechanics.

什么因素可能推动CYBQF股价上涨？

Upcoming: Regulatory approvals for HAL in key markets, such as the United States and Europe, could drive adoption and revenue growth.
Upcoming: Strategic partnerships with healthcare providers and industrial companies could expand CYBERDYNE's distribution network and market reach.
Ongoing: Increasing awareness of Cybernics Treatment and its potential benefits could lead to greater demand and adoption.
Ongoing: Technological advancements in robotics and neuroscience could enhance the capabilities of HAL and create new applications.

CYBQF的主要风险是什么？

Potential: Regulatory hurdles and delays in market approvals could impede CYBERDYNE's growth plans.
Potential: Competition from established medical device companies and emerging robotics firms could erode CYBERDYNE's market share.
Ongoing: Economic downturns and reduced healthcare spending could negatively impact CYBERDYNE's revenue and profitability.
Ongoing: The company's negative profit margin and high P/E ratio raise concerns about its financial sustainability.

CYBQF的核心优势是什么？

Innovative HAL technology with diverse applications.
Global presence and established partnerships.
Expertise in robotics, neuroscience, and biomechanics.
First-mover advantage in cybernics-based solutions.

CYBQF的劣势是什么？

Negative profit margin and high P/E ratio.
Reliance on regulatory approvals for market expansion.
Limited brand recognition compared to established medical device companies.
Potential for competition from emerging robotics firms.

CYBQF有哪些机遇？

Expansion of HAL in medical rehabilitation, industrial support, and disaster relief.
Adoption of Cybernics Treatment in healthcare facilities.
Development of new applications for HAL technology.
Strategic partnerships with healthcare providers, industrial companies, and government agencies.

CYBQF面临哪些威胁？

Regulatory hurdles and delays in market approvals.
Competition from established medical device companies and emerging robotics firms.
Economic downturns and reduced healthcare spending.
Technological advancements that could render HAL obsolete.

CYBQF的竞争对手是谁？

BICO AB — Focuses on bioprinting and lab automation solutions. — (BCCOY)
Brainsway Ltd — Develops non-invasive neuromodulation therapies. — (BRSYF)
Choice Health at Home Inc. — Provides home healthcare services. — (CHHHF)
Clearpoint Neuro Inc. — Offers neurosurgical navigation systems. — (CLLKF)
Jupiter Wellness Acquisition Corp — Focuses on wellness and consumer healthcare products. — (JWCTF)

Key Metrics

MoonshotScore: 58/100

Company Profile

Headquarters: Tsukuba, Japan
Employees: 211

AI Insight

AI analysis pending for CYBQF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does CYBERDYNE Inc. do?

CYBERDYNE Inc. is a robotics company specializing in the development, production, and distribution of robotic equipment and systems, primarily the Hybrid Assistive Limb (HAL). HAL is a wearable robot designed to enhance, support, and regenerate physical functions. The company's products and services cater to the medical, welfare, and industrial sectors, offering solutions for rehabilitation, mobility assistance, heavy labor support, and disaster relief. CYBERDYNE operates globally, with a focus on expanding the applications of its cybernics technology.

What do analysts say about CYBQF stock?

AI analysis is currently pending for CYBQF, so an analyst consensus is not available at this time. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Key valuation metrics to consider include the company's market capitalization, P/E ratio, gross margin, and growth potential. Factors to monitor include regulatory approvals, market adoption of HAL, and the company's ability to achieve profitability.

What are the main risks for CYBQF?

CYBERDYNE Inc. faces several risks, including regulatory hurdles, competition, and financial sustainability. Delays in regulatory approvals for HAL in key markets could impede the company's growth plans. Competition from established medical device companies and emerging robotics firms could erode CYBERDYNE's market share. The company's negative profit margin and high P/E ratio raise concerns about its financial sustainability. Additionally, economic downturns and reduced healthcare spending could negatively impact CYBERDYNE's revenue and profitability.